ALI adds multimodality version of UltraPACSALI Technologies continues to grow beyond its traditional role as an ultrasound miniPACS supplier. The Richmond, BC-based firm has introduced ALI UltraPACS NT Version 4, an image management system that
ALI Technologies continues to grow beyond its traditional role as an ultrasound miniPACS supplier. The Richmond, BC-based firm has introduced ALI UltraPACS NT Version 4, an image management system that can support major medical image modalities. ALI expects to begin shipping the new offering this year.
ALI plans to install its first beta site at Tower Radiology in Los Angeles, which will incorporate the UltraPACS unit into its CR, CT, MRI, fluoroscopy, nuclear medicine, and ultrasound clinical operations. ALI's UltraPACS will also connect two of Tower Radiology's imaging centers, creating a single imaging network with a common clinical database.
Since introducing its UltraPACS system, ALI has installed units at approximately 200 sites worldwide. In other ALI news, the company has received a 1998 Canada Export Award. The awards recognize Canadian firms that have successfully exported their products and services.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.